SI-BONE, which provides surgical joint implants for the alleviation of lower back pain, raised $108 million by offering 7.2 million shares at $15, the high end of the range of $13 to $15. The company had originally filed to offer 6.0 million shares at the same range. Insiders intended to purchase up to $32 million of the deal (30%).
SI-BONE plans to list on the Nasdaq under the symbol SIBN. Morgan Stanley and BofA Merrill Lynch acted as lead managers on the deal.
